FIELD: biotechnology.
SUBSTANCE: invention belongs to the field of biotechnology. Bispecific antibodies that specifically bind to Glipican 3 and CD3 epsilon have been proposed. The invention also relates to nucleic acids that encode bispecific antibodies, to vectors and cells for their expression, to a method for obtaining those antibodies. Besides, a pharmaceutical composition intended for treatment or prevention of various types of cancer is presented.
EFFECT: invention ensures bispecific antibodies’ high cytotoxic activity in relation to cells and tissues expressing Glipican 3, along with high-grade securirty.
10cl, 15 dwg, 14 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMATOXIN ANTIBODY-DRUG CONJUGATES AND USE THEREOF | 2020 |
|
RU2826004C2 |
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
| IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE | 2015 |
|
RU2722788C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO 4Rα (GD2 GANGLIOSIDE) AND ITS USE | 2021 |
|
RU2808563C2 |
| VARIANTS OF FC-REGION WITH MODIFIED ABILITY TO BIND TO FCRN AND WITH PRESERVED ABILITY TO BIND WITH PROTEIN A | 2015 |
|
RU2727639C2 |
| VERSIONS OF THE FC-DOMAIN WITH MODIFIED ABILITIES TO BIND TO FCRN | 2015 |
|
RU2730592C2 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, WHICH SPECIFICALLY BINDS TO BCMA, AND USE THEREOF | 2022 |
|
RU2820350C2 |
